Showing chemical card for Arbaclofen Placarbil (CFc000326079)
| Record Information | |
|---|---|
| Version | 1.0 |
| Creation Date | 2022-09-06 19:45:53 UTC |
| Update Date | 2022-09-14 04:59:21 UTC |
| Chemfont ID | CFc000326079 |
| Molecule Identification | |
| Common Name | Arbaclofen Placarbil |
| Definition | Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by XenoPort in 2011 for the treatment of GERD. On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis. |
| Structure |  |
| Synonyms | Not Available |
| Chemical Formula | |
| Average Molecular Weight | |
| Monoisotopic Molecular Weight | |
| IUPAC Name | |
| Traditional Name | |
| CAS Registry Number | 847353-30-4 |
| SMILES | Not Available |
| InChI Identifier | |
| InChI Key | |
| Chemical Taxonomy | |
| Classification | Not classified |
| Functional Ontology | |
| Physiological effect | Not Available |
| Disposition | |
| Process | Not Available |
| Role | Not Available |
| Physical Properties | |
| Predicted Properties | Not Available |
| External Links | |
| External Links | Not Available |
| References | |
| Synthesis Reference | Not Available |